Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs

Author's Avatar
Jun 14, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Michelle Frazier, Ph.D. to Coya’s management team as Senior Vice President of Regulatory Affairs. Dr. Frazier will leverage her regulatory and CMC expertise to guide and oversee all of Coya’s regulatory submissions including the upcoming IND submission for COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).